NZ572259A - Hla alleles associated with adverse drug reactions and methods for determining whether a patient carries said alleles - Google Patents
Hla alleles associated with adverse drug reactions and methods for determining whether a patient carries said allelesInfo
- Publication number
- NZ572259A NZ572259A NZ572259A NZ57225907A NZ572259A NZ 572259 A NZ572259 A NZ 572259A NZ 572259 A NZ572259 A NZ 572259A NZ 57225907 A NZ57225907 A NZ 57225907A NZ 572259 A NZ572259 A NZ 572259A
- Authority
- NZ
- New Zealand
- Prior art keywords
- substituted
- hla
- heterocyclic
- heteroaryl
- alkyl
- Prior art date
Links
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 44
- 108700028369 Alleles Proteins 0.000 title claims description 96
- 108010058607 HLA-B Antigens Proteins 0.000 claims abstract description 119
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims abstract description 112
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims abstract description 108
- 229940079593 drug Drugs 0.000 claims abstract description 68
- 239000003814 drug Substances 0.000 claims abstract description 68
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims abstract description 55
- 206010061623 Adverse drug reaction Diseases 0.000 claims abstract description 52
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000004044 response Effects 0.000 claims abstract description 9
- 229960001816 oxcarbazepine Drugs 0.000 claims abstract description 8
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims abstract description 4
- 230000001965 increasing effect Effects 0.000 claims abstract description 4
- 102000006390 HLA-B Antigens Human genes 0.000 claims abstract 5
- 239000000523 sample Substances 0.000 claims description 38
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 238000009396 hybridization Methods 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 210000004209 hair Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 239000013614 RNA sample Substances 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 114
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 110
- 125000000623 heterocyclic group Chemical class 0.000 description 109
- 125000001072 heteroaryl group Chemical group 0.000 description 106
- 229960000623 carbamazepine Drugs 0.000 description 94
- -1 e.g. Proteins 0.000 description 58
- 208000019502 Thymic epithelial neoplasm Diseases 0.000 description 49
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 46
- 230000002068 genetic effect Effects 0.000 description 44
- 229960003459 allopurinol Drugs 0.000 description 43
- 125000003118 aryl group Chemical group 0.000 description 34
- 125000000217 alkyl group Chemical group 0.000 description 33
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 31
- 125000003107 substituted aryl group Chemical class 0.000 description 25
- 125000005553 heteroaryloxy group Chemical group 0.000 description 24
- 125000000547 substituted alkyl group Chemical class 0.000 description 24
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 21
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 18
- 125000000753 cycloalkyl group Chemical class 0.000 description 18
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 239000003550 marker Substances 0.000 description 17
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 17
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 125000000304 alkynyl group Chemical group 0.000 description 15
- 229960002036 phenytoin Drugs 0.000 description 15
- 125000004426 substituted alkynyl group Chemical group 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 14
- 125000005000 thioaryl group Chemical group 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 125000005325 aryloxy aryl group Chemical group 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 201000005884 exanthem Diseases 0.000 description 12
- 206010037844 rash Diseases 0.000 description 12
- 125000004001 thioalkyl group Chemical group 0.000 description 12
- 208000010201 Exanthema Diseases 0.000 description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
- 102000054766 genetic haplotypes Human genes 0.000 description 10
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 125000005017 substituted alkenyl group Chemical group 0.000 description 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 206010037868 Rash maculo-papular Diseases 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 125000004423 acyloxy group Chemical group 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000010445 mica Substances 0.000 description 8
- 229910052618 mica group Inorganic materials 0.000 description 8
- 108020003285 Isocitrate lyase Proteins 0.000 description 7
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 7
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 125000000000 cycloalkoxy group Chemical group 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 125000005415 substituted alkoxy group Chemical group 0.000 description 7
- 108091092878 Microsatellite Proteins 0.000 description 6
- 239000001961 anticonvulsive agent Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229940125681 anticonvulsant agent Drugs 0.000 description 5
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 125000002795 guanidino group Chemical class C(N)(=N)N* 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 208000012965 maculopapular rash Diseases 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 229940090016 tegretol Drugs 0.000 description 4
- GDPHNAZHHDEGFH-UHFFFAOYSA-N 1-[carbamimidoyl-(diaminomethylideneamino)sulfamoyl]-1-(diaminomethylideneamino)guanidine Chemical compound N(C(=N)N)N(C(=N)N)S(=O)(=O)N(C(=N)N)NC(=N)N GDPHNAZHHDEGFH-UHFFFAOYSA-N 0.000 description 3
- 244000187656 Eucalyptus cornuta Species 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108090000958 Thiopurine S-methyltransferases Proteins 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 229960003022 amoxicillin Drugs 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
- 229960000991 ketoprofen Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
- 229960001940 sulfasalazine Drugs 0.000 description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- AETHRPHBGJAIBT-UHFFFAOYSA-N 1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]pyrazole-4-carboxylic acid Chemical compound C1=C(C#N)C(OCC(C)(C)C)=CC=C1N1N=CC(C(O)=O)=C1 AETHRPHBGJAIBT-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000028185 Angioedema Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 208000019872 Drug Eruptions Diseases 0.000 description 2
- 208000032678 Fixed drug eruption Diseases 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 108010028440 HLA-B*46:01 antigen Proteins 0.000 description 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 2
- 101150085390 RPM1 gene Proteins 0.000 description 2
- 208000032509 Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000004377 Thiopurine S-methyltransferases Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229940057922 carbatrol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 125000005240 diheteroarylamino group Chemical group 0.000 description 2
- 229940089063 epitol Drugs 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- 208000012587 fixed pigmented erythema Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000004731 long QT syndrome Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000000464 thioxo group Chemical group S=* 0.000 description 2
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
- XEEDURHPFVXALT-UHFFFAOYSA-N 4-hydroxyphenytoin Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC=CC=2)C(=O)NC(=O)N1 XEEDURHPFVXALT-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- FEEKFEKCXIDMIS-UHFFFAOYSA-N 5-(3,4-Dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin Chemical compound OC1C(O)C=CC(C2(C(NC(=O)N2)=O)C=2C=CC=CC=2)=C1 FEEKFEKCXIDMIS-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241001634822 Biston Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- PRGQOPPDPVELEG-UHFFFAOYSA-N Dihydroxycarbazepine Chemical compound OC1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 PRGQOPPDPVELEG-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 102000005486 Epoxide hydrolase Human genes 0.000 description 1
- 108020002908 Epoxide hydrolase Proteins 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010026122 HLA-A*33 antigen Proteins 0.000 description 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010024570 Lip swelling Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- WWEKVOUOQUHVHS-UHFFFAOYSA-N Phenytoin catechol Chemical compound C1=C(O)C(O)=CC=C1C1(C=2C=CC=CC=2)C(=O)NC(=O)N1 WWEKVOUOQUHVHS-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000005741 alkyl alkenyl group Chemical group 0.000 description 1
- 229940062334 aloprim Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001359 rheumatologic effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229940061414 trileptal Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ597628A NZ597628A (en) | 2006-05-11 | 2007-05-11 | Hla-b5801 allele associated with adverse drug reactions and methods for detecting such |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80012106P | 2006-05-11 | 2006-05-11 | |
| PCT/US2007/068782 WO2007134235A2 (en) | 2006-05-11 | 2007-05-11 | Hla alleles associated with adverse drug reactions and methods for detecting such |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ572259A true NZ572259A (en) | 2012-03-30 |
Family
ID=38694734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ572259A NZ572259A (en) | 2006-05-11 | 2007-05-11 | Hla alleles associated with adverse drug reactions and methods for determining whether a patient carries said alleles |
| NZ597628A NZ597628A (en) | 2006-05-11 | 2007-05-11 | Hla-b5801 allele associated with adverse drug reactions and methods for detecting such |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ597628A NZ597628A (en) | 2006-05-11 | 2007-05-11 | Hla-b5801 allele associated with adverse drug reactions and methods for detecting such |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7943309B2 (https=) |
| EP (1) | EP2016198B1 (https=) |
| JP (1) | JP2009536828A (https=) |
| KR (1) | KR101450348B1 (https=) |
| CN (1) | CN101454462A (https=) |
| AU (1) | AU2007249225B2 (https=) |
| BR (1) | BRPI0710436A8 (https=) |
| CA (1) | CA2651954C (https=) |
| DK (1) | DK2016198T3 (https=) |
| ES (1) | ES2422735T3 (https=) |
| IL (1) | IL194900A (https=) |
| MY (1) | MY150648A (https=) |
| NZ (2) | NZ572259A (https=) |
| PL (1) | PL2016198T3 (https=) |
| PT (1) | PT2016198E (https=) |
| TW (1) | TWI335937B (https=) |
| WO (1) | WO2007134235A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220259655A1 (en) * | 2019-05-06 | 2022-08-18 | Chang Gung Memorial Hospital, Linkou | Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1536021A1 (en) * | 2003-11-27 | 2005-06-01 | Consortium National de Recherche en Genomique (CNRG) | Method for HLA typing |
| WO2011130152A2 (en) * | 2010-04-12 | 2011-10-20 | Academia Sinica | Method for identifying hla complexes associated with adverse drug reactions |
| JP5959634B2 (ja) * | 2011-06-23 | 2016-08-02 | チャン グン メディカル ファンデーション チャン グン メモリアル ホスピタル アット キールン | フェニトインによって誘発される薬の副作用のリスク評価 |
| CN102296109A (zh) * | 2011-06-30 | 2011-12-28 | 北京思尔成生物技术有限公司 | HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒 |
| US20150225788A1 (en) | 2011-12-12 | 2015-08-13 | Wen-Hung Chung | Risk assessment for phenytoin-induced adverse drug reactions |
| CN102660635B (zh) * | 2012-01-14 | 2014-03-12 | 长沙三济生物科技有限公司 | 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒 |
| CN103114138B (zh) * | 2013-01-27 | 2014-12-03 | 复旦大学 | Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒 |
| SG11201601761QA (en) * | 2013-09-17 | 2016-04-28 | Agency Science Tech & Res | Method for detection of a genetic variant |
| CN104017898B (zh) * | 2014-06-25 | 2016-04-27 | 上海荻硕贝肯生物科技有限公司 | 快速检测hla-b*5801等位基因的引物、试剂盒及方法 |
| CN104232781B (zh) * | 2014-09-26 | 2017-04-19 | 陕西佰美基因股份有限公司 | 一种检测HLA‑B*5801等位基因的TaqMan探针实时荧光PCR方法 |
| CN106119362B (zh) * | 2016-06-30 | 2019-09-10 | 江苏伟禾生物科技有限公司 | 一种用于检测hla-b*1502等位基因的引物组及试剂盒 |
| CN108929902B (zh) * | 2018-07-28 | 2022-03-25 | 北京博奥晶典生物技术有限公司 | 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法 |
| CN109355358A (zh) * | 2018-10-22 | 2019-02-19 | 江苏美因康生物科技有限公司 | 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法 |
| CN109554460B (zh) * | 2018-12-17 | 2022-03-22 | 上海市疾病预防控制中心 | 一种基于hla基因多态性位点预测h7n9易感人群的检测方法及其用途 |
| TWI804620B (zh) * | 2019-05-06 | 2023-06-11 | 長庚醫療財團法人林口長庚紀念醫院 | 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途 |
| CN111620924A (zh) * | 2020-06-04 | 2020-09-04 | 华中农业大学 | 基于天然产物的药物设计方法、五环三萜类化合物、其制备方法及应用 |
| CN113308532A (zh) * | 2021-05-28 | 2021-08-27 | 上海康黎诊断技术有限公司 | 一种用于检测人hla-b*1502基因突变的特异性引物探针组合及其试剂盒，以及方法 |
| WO2023080478A1 (ko) * | 2021-11-02 | 2023-05-11 | 주식회사 랩 지노믹스 | Ｈｌａ－ｂ＊5801 대립유전자 검출용 핵산 분자 및 이를 이용한 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583238A (en) * | 1990-11-19 | 1996-12-10 | G. D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
| ES2123775T5 (es) * | 1993-03-18 | 2005-10-01 | N.V. Innogenetics S.A. | Procedimiento para la tipificacion de hla-b por medio de iniciadores especificos y conjuntos de sondas. |
| US5550039A (en) | 1995-03-07 | 1996-08-27 | Hoffmann-La Roche Inc. | Oligonucleotide primers for HLA class I B locus DNA typing |
| US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| AU2004212328B2 (en) * | 2003-02-17 | 2008-01-17 | Novartis Ag | Use of S-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders |
| US7470513B2 (en) * | 2003-11-10 | 2008-12-30 | Academia Sinica | Risk assessment for adverse drug reactions |
-
2007
- 2007-05-11 PT PT77974327T patent/PT2016198E/pt unknown
- 2007-05-11 NZ NZ572259A patent/NZ572259A/en not_active IP Right Cessation
- 2007-05-11 EP EP07797432.7A patent/EP2016198B1/en not_active Revoked
- 2007-05-11 JP JP2009510183A patent/JP2009536828A/ja active Pending
- 2007-05-11 NZ NZ597628A patent/NZ597628A/xx not_active IP Right Cessation
- 2007-05-11 AU AU2007249225A patent/AU2007249225B2/en not_active Ceased
- 2007-05-11 TW TW096116910A patent/TWI335937B/zh active
- 2007-05-11 BR BRPI0710436A patent/BRPI0710436A8/pt not_active Application Discontinuation
- 2007-05-11 KR KR1020087027562A patent/KR101450348B1/ko active Active
- 2007-05-11 CA CA2651954A patent/CA2651954C/en active Active
- 2007-05-11 US US11/747,674 patent/US7943309B2/en active Active
- 2007-05-11 PL PL07797432T patent/PL2016198T3/pl unknown
- 2007-05-11 WO PCT/US2007/068782 patent/WO2007134235A2/en not_active Ceased
- 2007-05-11 CN CNA2007800170212A patent/CN101454462A/zh active Pending
- 2007-05-11 MY MYPI20084331 patent/MY150648A/en unknown
- 2007-05-11 ES ES07797432T patent/ES2422735T3/es active Active
- 2007-05-11 DK DK07797432.7T patent/DK2016198T3/da active
-
2008
- 2008-10-23 IL IL194900A patent/IL194900A/en active IP Right Grant
-
2011
- 2011-05-04 US US13/100,665 patent/US8142999B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220259655A1 (en) * | 2019-05-06 | 2022-08-18 | Chang Gung Memorial Hospital, Linkou | Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2651954A1 (en) | 2007-11-22 |
| US20080145846A1 (en) | 2008-06-19 |
| AU2007249225A1 (en) | 2007-11-22 |
| DK2016198T3 (en) | 2013-07-15 |
| PT2016198E (pt) | 2013-07-29 |
| US8142999B2 (en) | 2012-03-27 |
| IL194900A0 (en) | 2009-08-03 |
| PL2016198T3 (pl) | 2013-12-31 |
| BRPI0710436A2 (pt) | 2012-10-09 |
| NZ597628A (en) | 2013-07-26 |
| EP2016198A4 (en) | 2010-07-21 |
| KR20090031671A (ko) | 2009-03-27 |
| AU2007249225B2 (en) | 2013-06-27 |
| WO2007134235A2 (en) | 2007-11-22 |
| MY150648A (en) | 2014-02-14 |
| EP2016198A2 (en) | 2009-01-21 |
| CN101454462A (zh) | 2009-06-10 |
| WO2007134235A3 (en) | 2008-01-17 |
| KR101450348B1 (ko) | 2014-10-14 |
| IL194900A (en) | 2013-02-28 |
| ES2422735T3 (es) | 2013-09-13 |
| EP2016198B1 (en) | 2013-05-01 |
| US20110212439A1 (en) | 2011-09-01 |
| TW200844238A (en) | 2008-11-16 |
| CA2651954C (en) | 2014-02-25 |
| TWI335937B (en) | 2011-01-11 |
| BRPI0710436A8 (pt) | 2018-06-26 |
| US7943309B2 (en) | 2011-05-17 |
| JP2009536828A (ja) | 2009-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ572259A (en) | Hla alleles associated with adverse drug reactions and methods for determining whether a patient carries said alleles | |
| AU2004289951B2 (en) | Risk assessment for adverse drug reactions | |
| Koo et al. | Polymorphisms of KCNJ11 (Kir6. 2 gene) are associated with Type 2 diabetes and hypertension in the Korean population | |
| WO2008003826A1 (en) | Novel genes and markers in essential arterial hypertension | |
| Feng et al. | Association of the PTPN22 gene (‐1123G> C) polymorphism with rheumatoid arthritis in Chinese patients | |
| AU2013219191A1 (en) | Hla alleles associated with adverse drug reactions and methods for detecting such | |
| US8236497B2 (en) | Methods of diagnosing cardiovascular disease | |
| JP2006500930A (ja) | 免疫抑制療法に際してのコレステロール上昇予知方法 | |
| US8080374B2 (en) | Methods of diagnosing cardiovascular disease | |
| HK1134325A (en) | Hla alleles associated with adverse drug reactions and methods for detecting such |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 MAY 2017 BY COMPUTER PACKAGES INC Effective date: 20140528 |
|
| LAPS | Patent lapsed |